Bitget App
Trade smarter
Buy cryptoMarketsTradeFuturesStocksEarnInstitutionAI & More
Vita Coco Q3 net income rises 46% to $35.02 million; Q3 net sales climb 34% to $243.83 million

Vita Coco Q3 net income rises 46% to $35.02 million; Q3 net sales climb 34% to $243.83 million

BitgetBitget2026/10/22 11:04
  • Vita Coco’s third-quarter 2026 net income climbed 46% year-over-year to $35.02 million, benefiting from higher gross profit.
  • Net sales rose 34% year-over-year to $243.83 million, driven by volume gains in coconut water and private label.
  • The July acquisition of Copra added super-premium Thai Nam Hom coconut water products to the portfolio.
  • Full-year FY26 net sales guidance increased to $810 million–$820 million, supported by coconut water growth, private label trends and Copra.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. The Vita Coco Company Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610220700PRIMZONEFULLFEED9851074) on October 22, 2026, and is solely responsible for the information contained therein.

0
0

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.
Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.
Trade now!

You may also like

GM cancels long-term rare earth permanent magnet supply agreement in the US; supplier initiates arbitration

General Motors (GM.US) has canceled a long-term supply agreement with a U.S. rare earth permanent magnet manufacturer, and both parties are currently undergoing arbitration.

智通财经•2026/10/23 03:27
GM cancels long-term rare earth permanent magnet supply agreement in the US; supplier initiates arbitration

Allergy and autoimmune biotechnology company Lycia Therapeutics (LYCA.US) will be listed on Nasdaq tonight! IPO priced at $18 per share, aiming to raise $317.5 millions.

Lycia will issue 17.64 million shares at a price of $18 per share to raise $317.5 million.

智通财经•2026/10/23 02:47